第三方粪菌移植治疗高危初治下消化道急性移植物抗宿主病
这项开放标签、单臂、先导性研究将第三方单一供体粪菌移植(FMT)联合全身性糖皮质激素用于高危急性下消化道GVHD参与者,重点为初治病例。主要终点为可行性,10例参与者中9例完成全部合格剂量,第28天器官特异性下消化道完全缓解率为70%。探索性分析提示FMT后α多样性增加,并观察到供体来源菌种扩增及色氨酸代谢物和短链脂肪酸增加。
要点
- 10例高危急性下消化道GVHD参与者接受第三方单一供体FMT联合全身性糖皮质激素,其中9例为初治病例。
- 研究达到主要可行性终点,10例中9例完成全部合格剂量。
- 第28天器官特异性下消化道完全缓解率为70%,所有应答者初始临床应答在1周内出现且完全缓解者无下消化道GVHD复发。
核心结论
- 在高危急性下消化道GVHD参与者中,第三方单一供体FMT联合全身性糖皮质激素达到主要可行性终点,第28天器官特异性下消化道完全缓解率为70%。
- 探索性分析提示FMT后α多样性增加,并观察到供体来源菌种扩增及色氨酸代谢物和短链脂肪酸增加。
- 原文结论认为有必要研究在急性下消化道GVHD治疗范式中更早使用微生物组靶向干预。
研究设计与样本
- 开放标签、单臂、先导性研究,第三方单一供体FMT联合全身性糖皮质激素用于高危急性下消化道GVHD参与者,重点为初治病例。
- 参与者计划接受1剂诱导剂量(每天15粒胶囊,连续2天),随后3剂每周维持剂量(每剂15粒胶囊)。
- 主要终点为可行性,若≥80%的参与者能够吞服75粒计划胶囊中的≥40粒即达到该终点。
- 共纳入并治疗10例参与者,其中9例为初治病例,1例为激素难治性病例。
- 该试验在www.ClinicalTrials.gov注册,注册号为#NCT04139577。
主要发现
- 研究达到主要终点,10例参与者中9例完成全部合格剂量。
- 第28天器官特异性下消化道完全缓解率为70%。
- 所有应答者的初始临床应答在1周内出现,完全缓解者的临床应答持久且无下消化道GVHD复发。
- 探索性分析提示FMT后α多样性增加。
- 受者微生物组组成从未达到高度供体相似性,但在FMT后前7天内观察到供体来源菌种扩增及色氨酸代谢物和短链脂肪酸增加。
局限性
- 原文结论指出有必要研究在急性下消化道GVHD治疗范式中更早使用微生物组靶向干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Disruption of the intestinal microbiome is observed with acute graft-versus-host disease (GVHD) of the lower gastrointestinal (LGI) tract, and fecal microbiota transplantation (FMT) has successfully cured steroid-refractory cases. In this open-label, single-arm, pilot study, third-party, single-donor FMT was administered in combination with systemic corticosteroids to participants with high-risk acute LGI GVHD, with a focus on treatment-naïve cases. Participants were scheduled to receive 1 induction dose (15 capsules per day for 2 consecutive days), followed by 3 weekly maintenance doses, consisting of 15 capsules per dose. The primary end point of the study was feasibility, which would be achieved if ≥80% of participants able to swallow ≥40 of the 75 scheduled capsules. Ten participants (9 treatment-naïve; 1 steroid-refractory) were enrolled and treated. The study met the primary end point, with 9 of 10 participants completing all eligible doses. Organ-specific LGI complete response rate at day 28 was 70%. Initial clinical response was observed within 1 week for all responders, and clinical responses were durable without recurrent LGI GVHD in complete responders. Exploratory analyses suggest that alpha diversity increased after FMT. Although recipient microbiome composition never achieved a high degree of donor similarity, expansion of donor-derived species and increases in tryptophan metabolites and short-chain fatty acids were observed within the first 7 days after FMT. Investigation into the use of microbiome-targeted interventions earlier in the treatment paradigm for acute LGI GVHD is warranted. This trial was registered at www.ClinicalTrials.gov as #NCT04139577.
引用
- DeFilipp Z, Damania AV, Kim HT, et al. Third-party fecal microbiota transplantation for high-risk treatment-naïve acute GVHD of the lower GI tract. Blood Adv. 2024. PMID: 38471063. doi:10.1182/bloodadvances.2024012556
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。